Microbiome, antibiotics and irritable bowel syndrome

British Medical Bulletin

Volumn 120, Issue 1, 2016, Pages 91-99

  Ahmad, O F ^a   Akbar, A ^b  

^a WHITTINGTON HOSPITAL   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Antibiotics; Dysbiosis; Inflammation; Irritable bowel syndrome; Microbiota

Indexed keywords

ANTIBIOTIC AGENT; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN; TLR4 PROTEIN, HUMAN; TLR5 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5;

BACTERIAL OVERGROWTH; DRUG EFFICACY; HOST; HUMAN; INTESTINE FLORA; IRRITABLE COLON; MEDLINE; META ANALYSIS (TOPIC); MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SMALL INTESTINE; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; ANIMAL; DRUG EFFECTS; EVIDENCE BASED MEDICINE; IMMUNOLOGY; MICROBIOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL MICROBIOME; HUMANS; IRRITABLE BOWEL SYNDROME; RIFAMYCINS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 5; TREATMENT OUTCOME;

EID: 85015031233     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldw038     Document Type: Review

References (64)

1. Simrén M, Svedlund J, Posserud I, et al. Health-related quality of life in patients attending a gastroenterology outpatient clinic: functional disorders versus organic diseases. Clin Gastroenterol Hepatol. 2006;4:187-95.
2. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006; 130:1480-91.
3. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. AJP Gastrointest Liver Physiol. 2012;303:G775-85.
4. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163-73.
5. Biasucci G, Benenati B, Morelli L, et al. Cesarean delivery may affect the early biodiversity of intestinal bacteria. J Nutr. 2008;138:1796S-1800S.
6. Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci. 2010;107:11971-5.
7. Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5:e177.
8. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2016;124:837-48.
9. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107-33.
10. Zoetendal EG, Rajilic-Stojanovic M, de Vos WM. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut. 2008;57: 1605-15.
11. Qin J, Li R, Raes J, et al. A human gut microbial gene catalog established by metagenomic sequencing. Nature. 2010;464:59-65.
12. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688-93.
13. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80.
14. Koren O, Knights D, Gonzalez A, et al. A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets. PLoS Comput Biol. 2013;9:e1002863.
15. Jeffery IB, Claesson MJ, O'Toole PW, et al. Categorization of the gut microbiota: enterotypes or gradients? Nat Rev Microbiol. 2012;10:591-2.
16. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol. 2002;16:915-31.
17. Wostmann BS, Larkin C, Moriarty A, et al. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab Anim Sci. 1983;33: 46-50.
18. Xu J, Bjursell MK, Himrod J, et al. A genomic view of the human-bacteroides thetaiotaomicron symbiosis. Science. 2003;299:2074-6.
19. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718-23.
20. Rajilic-Stojanovic M, Heilig HG, Tims S, et al. Longterm monitoring of the human intestinal microbiota composition. Environ Microbiol. 2013;15:1146-59.
21. Faith JJ, Guruge JL, Charbonneau M, et al. The longterm stability of the human gut microbiota. Science. 2013;341:1237439.
22. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535-44.
23. Jalanka-Tuovinen J, Salojarvi J, Salonen A, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014;63:1737-45.
24. Sundin J, Rangel I, Fuentes S, et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther. 2015;41:342-51.
25. Akbar A, Yiangou Y, Facer P, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57:923-9.
26. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12:449-57.
27. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003; 98:1578-83.
28. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392-400.
29. Guilarte M, Santos J, de Torres I, et al. Diarrhoeapredominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203-9.
30. Park JH, Rhee P-L, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21:71-8.
31. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693-702.
32. Barbara G, Wang B, Stanghellini V, et al. Mast celldependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26-37.
33. Brint EK, MacSharry J, Fanning A, et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol. 2011;106: 329-36.
34. Schoepfer AM, Schaffer T, Seibold-Schmid B, et al. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil. 2008;20:1110-8.
35. Barbara G. Editorial: toll-like receptor expression in irritable bowel syndrome: on the alert for a microbial threat [quest]. Am J Gastroenterol. 2011;106: 337-9.
36. Dinan TG, Quigley EMM, Ahmed SMM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130:304-11.
37. Darkoh C, Comer L, Zewdie G, et al. Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. PLoS One. 2014;9:e93144.
38. Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43:37-49.
39. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334-40.
40. Ford AC, Spiegel BMR, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279-86.
41. Shah ED, Basseri RJ, Chong K, et al. Abnormal breath testing in IBS: A meta-analysis. Dig Dis Sci. 2010;55: 2441-9.
42. Rajilic-Stojanovic M, Jonkers DM, Salonen A, et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol. 2015; 110:278-87.
43. Bennet SMP, Ohman L, Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. Gut Liver. 2015;9:318-31.
44. Rajilic-Stojanovic M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141: 1792-801.
45. Malinen E, Krogius-Kurikka L, Lyra A, et al. Association of symptoms with gastrointestinal microbiota in irritable bowel syndrome. World J Gastroenterol. 2010;16:4532-40.
46. Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil. 2012;24:31-9.
47. Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil. 2013;25:e272-82.
48. Johnson AC, Greenwood-Van Meerveld B, McRorie J. Effects of bifidobacterium infantis 35624 on postinflammatory visceral hypersensitivity in the rat. Dig Dis Sci. 2011;56:3179-86.
49. Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology. 2009;137:1425-34.
50. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut. 2013;62:159-76.
51. Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther. 2014;39:1033-42.
52. Bonfrate L, Tack J, Grattagliano I, et al. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol. 2013;48:995-1009.
53. Mendall MA, Kumar D. Antibiotic use, childhood affluence and irritable bowel syndrome (IBS). Eur J Gastroenterol Hepatol. 1998;10:59-62.
54. Paula H, Grover M, Halder SL, et al. Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders. Neurogastroenterol Motil. 2015;27:1580-6.
55. Maxwell PR, Rink E, Kumar D, et al. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol. 2002;97:104-8.
56. Nayak AK, Karnad DR, Abraham P, et al. Metronidazole relieves symptoms in irritable bowel syndrome: The confusion with so-called "chronic amebiasis". Indian J Gastroenterol. 1997;16:137-9.
57. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-9.
58. Pimentel M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297-301.
59. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med. 2006;145:557-63.
60. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-33.
61. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364: 22-32.
62. Lembo A, Pimentel M, Rao SS, et al. Efficacy and safety of repeat treatment with rifaximin for diarrheapredominant irritable bowel syndrome (IBS-D): results of the TARGET 3 study. Paper presented at the 2014 Annual Scientific Meeting of the American College of Gastroenterology; 17-22 October 2014; Philadelphia, PA. Abstract 45.
63. Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol. 2012;107:28-35quiz 36.
64. Shah E, Kim S, Chong K, et al. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med. 2012;125:381-93.